Key Takeaways
- Moderna (MRNA) has secured a new FDA PDUFA date of August 5, 2026, for its mRNA-1010 flu vaccine, positioning the company for a potential market launch by this fall.
- UBS (UBS) has upwardly revised its forecast for Big Tech bond sales this year, anticipating a surge in corporate debt issuance as firms capitalize on stable yields to fund AI infrastructure.
- German Chancellor Friedrich Merz is signaling a push for a German successor to the ECB Presidency, following reports that Christine Lagarde may consider an early departure to facilitate a leadership transition.
- Moderna’s leadership called for "consistent" regulatory guidance after the FDA initially issued a refusal-to-file letter, a move the company argued shifted the "rules of the game" mid-process.
Moderna Targets Fall Launch for mRNA Flu Vaccine
Moderna (MRNA) President Stephen Hoge announced that the U.S. Food and Drug Administration (FDA) has officially agreed to review the company’s biologics license application for its investigational seasonal influenza vaccine, mRNA-1010. The agency has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026, which would allow for a commercial rollout in time for the 2026/2027 flu season.
The breakthrough follows a period of regulatory friction where the FDA initially issued a "Refusal-to-File" letter regarding the vaccine's comparator studies. In a recent interview, Hoge emphasized that the industry requires "clear regulatory rules applied consistently," noting that the company has now agreed to an additional post-marketing requirement study for older adults to satisfy agency concerns.
UBS Lifts Forecast for Big Tech Debt Issuance
UBS (UBS) has raised its 2026 projections for bond sales among major technology firms, citing a favorable environment for investment-grade corporate debt. Analysts suggest that "Big Tech" entities—including the likes of Microsoft (MSFT) and Alphabet (GOOGL)—are increasingly looking to the bond market to finance massive capital expenditures required for artificial intelligence and data center expansion.
The revised forecast comes as market volatility remains low and interest rates are expected to hold steady or decline through the latter half of the year. UBS (UBS) noted that high-grade corporate bonds remain a primary source of yield and diversification for investors, further incentivizing large-scale issuance from cash-rich tech giants.
Germany Eyes ECB Leadership Amid Succession Speculation
A spokesman for German Chancellor Friedrich Merz stated on Wednesday that Germany could propose a German candidate to lead the European Central Bank (ECB). This political signaling follows reports that current ECB President Christine Lagarde may step down before her term ends in 2027 to ensure her successor is chosen by moderate European leaders before upcoming regional elections.
Potential candidates frequently mentioned in Berlin include Bundesbank President Joachim Nagel, as Germany seeks to exert greater influence over eurozone monetary policy. While an ECB spokesperson maintained that Lagarde is "focused on her mission," traders are closely watching for shifts in the central bank's senior ranks as Vice President Luis de Guindos also nears the end of his term.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.